Dose-effect	dose-effect	O	O	O	O
and	and	O	O	O	O
structure-function	structure-function	O	O	O	O
relationships	relationships	O	O	O	O
in	in	O	O	O	O
doxorubicin	doxorubicin	CHEMICALS	O	OTHERS	I
cardiomyopathy	cardiomyopathy	O	DISEASE	OTHERS	I
.	.	O	O	O	O

The	the	O	O	O	O
cardiomyopathy	cardiomyopathy	O	DISEASE	OTHERS	I
(	(	O	O	O	O
CM	cm	O	DISEASE	OTHERS	I
)	)	O	O	O	O
produced	produced	O	O	O	O
by	by	O	O	O	O
the	the	O	O	O	O
anticancer	anticancer	O	O	O	O
drug	drug	O	O	O	O
doxorubicin	doxorubicin	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
DXR	dxr	O	O	OTHERS	I
)	)	O	O	O	O
(	(	O	O	O	O
Adriamycin	adriamycin	CHEMICALS	O	OTHERS	I
)	)	O	O	O	O
provides	provides	O	O	O	O
a	a	O	O	O	O
unique	unique	O	O	O	O
opportunity	opportunity	O	O	O	O
to	to	O	O	O	O
analyze	analyze	O	O	O	O
dose-effect	dose-effect	O	O	O	O
and	and	O	O	O	O
structure-function	structure-function	O	O	O	O
relationships	relationships	O	O	O	O
during	during	O	O	O	O
development	development	O	O	O	O
of	of	O	O	O	O
myocardial	myocardial	O	O	OTHERS	I
disease	disease	O	O	OTHERS	I
.	.	O	O	O	O

We	we	O	O	O	O
measured	measured	O	O	O	O
the	the	O	O	O	O
degree	degree	O	O	O	O
of	of	O	O	O	O
morphologic	morphologic	O	O	O	O
damage	damage	O	O	O	O
by	by	O	O	O	O
ultrastructural	ultrastructural	O	O	O	O
examination	examination	O	O	O	O
of	of	O	O	O	O
endomyocardial	endomyocardial	O	O	O	O
biopsy	biopsy	O	O	O	O
and	and	O	O	O	O
the	the	O	O	O	O
degree	degree	O	O	O	O
of	of	O	O	O	O
performance	performance	O	O	O	O
abnormally	abnormally	O	O	O	O
by	by	O	O	O	O
right	right	O	O	O	O
heart	heart	O	O	O	O
catheterization	catheterization	O	O	O	O
in	in	O	O	O	O
patients	patients	O	O	O	O
receiving	receiving	O	O	O	O
DXR	dxr	O	O	OTHERS	I
.	.	O	O	O	O

Morphologic	morphologic	O	O	O	O
damage	damage	O	O	O	O
was	was	O	O	O	O
variable	variable	O	O	O	O
but	but	O	O	O	O
was	was	O	O	O	O
proportional	proportional	O	O	O	O
to	to	O	O	O	O
the	the	O	O	O	O
total	total	O	O	O	O
cumulative	cumulative	O	O	O	O
DXR	dxr	O	O	OTHERS	I
dose	dose	O	O	O	O
between	between	O	O	O	O
100	100	O	O	O	O
and	and	O	O	O	O
600	600	O	O	O	O
mg/m2	mg/m2	O	O	O	O
.	.	O	O	O	O

Performance	performance	O	O	O	O
abnormalities	abnormalities	O	O	O	O
correlated	correlated	O	O	O	O
weakly	weakly	O	O	O	O
with	with	O	O	O	O
dose	dose	O	O	O	O
,	,	O	O	O	O
exhibited	exhibited	O	O	O	O
a	a	O	O	O	O
curvilinear	curvilinear	O	O	O	O
relationship	relationship	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
had	had	O	O	O	O
a	a	O	O	O	O
"	"	O	O	O	O
threshold	threshold	O	O	O	O
"	"	O	O	O	O
for	for	O	O	O	O
expression	expression	O	O	O	O
.	.	O	O	O	O

Catheterization	catheterization	O	O	O	O
abnormalities	abnormalities	O	O	O	O
correlated	correlated	O	O	O	O
well	well	O	O	O	O
with	with	O	O	O	O
morphologic	morphologic	O	O	O	O
damage	damage	O	O	O	O
(	(	O	O	O	O
r	r	O	O	O	O
=	=	O	O	O	O
0.57	0.57	O	O	O	O
to	to	O	O	O	O
0.78	0.78	O	O	O	O
)	)	O	O	O	O
in	in	O	O	O	O
a	a	O	O	O	O
subgroup	subgroup	O	O	O	O
of	of	O	O	O	O
patients	patients	O	O	O	O
in	in	O	O	O	O
whom	whom	O	O	O	O
exercise	exercise	O	O	O	O
hemodynamics	hemodynamics	O	O	O	O
were	were	O	O	O	O
measured	measured	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
this	this	O	O	O	O
relationship	relationship	O	O	O	O
also	also	O	O	O	O
exhibited	exhibited	O	O	O	O
a	a	O	O	O	O
curvilinear	curvilinear	O	O	O	O
,	,	O	O	O	O
threshold	threshold	O	O	O	O
configuration	configuration	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
DXR-CM	dxr-cm	O	O	O	O
myocardial	myocardial	O	DISEASE	OTHERS	I
damage	damage	O	DISEASE	OTHERS	I
is	is	O	O	O	O
proportional	proportional	O	O	O	O
to	to	O	O	O	O
the	the	O	O	O	O
degree	degree	O	O	O	O
of	of	O	O	O	O
cytotoxic	cytotoxic	O	O	O	O
insult	insult	O	O	O	O
(	(	O	O	O	O
DXR	dxr	O	O	OTHERS	I
dose	dose	O	O	O	O
)	)	O	O	O	O
while	while	O	O	O	O
myocardial	myocardial	O	O	O	O
function	function	O	O	O	O
is	is	O	O	O	O
preserved	preserved	O	O	O	O
until	until	O	O	O	O
a	a	O	O	O	O
critical	critical	O	O	O	O
dose	dose	O	O	O	O
or	or	O	O	O	O
degree	degree	O	O	O	O
of	of	O	O	O	O
damage	damage	O	O	O	O
is	is	O	O	O	O
reached	reached	O	O	O	O
,	,	O	O	O	O
after	after	O	O	O	O
which	which	O	O	O	O
myocardial	myocardial	O	O	O	O
performance	performance	O	O	O	O
deteriorates	deteriorates	O	O	O	O
rapidly	rapidly	O	O	O	O
.	.	O	O	O	O

